GlassScriptPhysician profile
Christopher Brady Bledsoe
NPI 1770875205
$24,822.15
in general payments reported to CMS, 2019-2025
47 companies · $4,387 in 2025
The $4,387 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $2,576 · 2021: $2,751 · 2022: $3,821 · 2023: $6,284 · 2024: $4,467 · 2025: $4,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $1,750 · Education: $621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,766.49 |
| Consulting Fee | $1,750.00 |
| Education | $621.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,128.08 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $2,738.50 | 2019-2025 | |
| Janssen Biotech, INC. | $2,177.73 | 2019-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $1,977.38 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $1,619.74 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Regeneron Healthcare Solutions, INC. | $1,534.76 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $1,253.09 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $1,241.03 | 2019-2025 | |
| Leo Pharma INC. | $1,229.74 | 2020-2025 | Adbry, Anzupgo, Spevigo |
| Amgen INC. | $745.20 | 2020-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $643.49 | 2019-2025 | Jublia, Arazlo, Cabtreo |
| E.R. Squibb & Sons, L.L.C. | $621.71 | 2022-2025 | Sotyktu |
| Pfizer INC. | $610.98 | 2019-2025 | |
| Ucb, INC. | $577.84 | 2019-2025 | Bimzelx |
| Incyte Corporation | $517.46 | 2021-2025 | Opzelura, Opzelura |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bledsoe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.